Home » Pharmaceuticals

Non-Small Cell Lung Cancer (NSCLC): Dynamic Market Forecast to 2025

The NSCLC therapeutics market is a rapidly evolving field in which new developments are constantly influencing the landscape. The Forecast Update is designed to help clients stay abreast of the latest news in the NSCLC space, including regulatory, commercial, and clinical events, and to understand how these events will impact the market forecast.


Key events covered in the Forecast Update include:

Regulatory filings

Approval decisions

Pricing changes

Patent litigation

Clinical trial data announcements

Clinical trial failures

Clinical trial timeline updates

The Forecast Update consists of a slide deck detailing key market-impacting events that have occurred since the last publication of the PharmaPoint: NSCLC report, along with an updated Excel-based forecast model which reflects the projected influence of these events on the future NSCLC market.

Components of the slide deck include:

Timeline of market-impacting events

Key clinical trial landscape updates

Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective

Overview of updates to the forecast model based on anticipated future impact of events

Forward-looking events calendar listing expected key updates to the NSCLC competitive space in the next quarter

Key Highlights

Updates in the NSCLC space since the last report including:

Recent regulatory events

Recent commercial events

Recent clinical events

Market dynamics in the frontline NSCLC setting

Landscape changes in the EGFR-mutant NSCLC setting

Projected treatment algorithm shifts in the ALK-mutant NSCLC setting

Table of Contents

Table of Contents (PowerPoint Deck)

1 Dynamic Market Forecast Overview

1.1 Related Reports

1.2 Upcoming Related Reports

2 Executive Summary

2.1 Key Events in Update

2.2 Updates to Treatment Algorithms

2.3 Clinical Trial Landscape Updates

2.4 Pipeline Landscape Updates

2.5 Market Insight on Key Events

3 Event 1: Market Dynamics Shift in Frontline NSCLC

3.1 Key Updates to the Frontline Setting – Elderly Patients

3.2 Merck & Co., Keytruda (pembrolizumab)

3.3 AstraZeneca, Imfinzi (durvalumab) + tremelimumab

3.4 Pfizer and Merck KGaA , Bavencio (avelumab)

3.5 Roche, Tecentriq (atezolizumab)

3.6 Novartis, Tafinlar (dabrafenib) + Mekinist (trametinib)

3.7 Additional Clinical Trial Updates- Frontline Setting

3.8 Summary/Trends

3.9 Sources

4 Event 2: Weak Competition in the EGFRm+ Segment Creates Opportunity for Tagrisso

4.1 Key Updates to the EGFRm+ Segment

4.2 AstraZeneca, Tagrisso (osimertinib)

4.3 Pfizer, dacomitinib

4.4 Additional Clinical Trial Updates- EGFRm+ Setting

4.5 Summary/Trends

4.6 Sources

5 Event 3: New SOC Anticipated in the ALKm+ 1L Setting

5.1 Key Updates to the ALKm+ Setting

5.2 Roche, Alecensa (alectinib)

5.3 Takeda, Alunbrig (brigatinib)

5.4 Pfizer, lorlatinib

5.5 Summary/Trends

5.6 Sources

6 Other Events of Interest

6.1 Various Developers

6.2 Sources

7 Dynamic Market Forecast Highlights

7.1 Updates to Frontline NSCLC Segment

7.2 Updates to EGFRm+ NSCLC Segment

7.3 Updates to ALKm+ NSCLC Segment

7.4 Selected Additional Forecast Updates

8 Events Calendar

8.1 Key Clinical Events Expected in Q4 2017

9 Appendix

9.1 Methodology

9.2 Primary Research

9.3 About the Authors

9.4 About the Authors

9.5 Contact Us

9.6 Disclaimer


Discounts available for multiple purchases.

+44 20 7947 2960

Join our mailing list

Saved reports